Background: Colorectal carcinoma (CRC) is a common cause of cancer-related death worldwide. 5-fluorouracil (5-FU), a first-line chemotherapeutic drug in CRC, has several side effects limiting its therapeutic outcomes. Quercetin (QU) is a dietary bioflavonoid with antioxidant and cytotoxic prooxidant properties. Here, we hypothesize that combination treatment with QU and 5-FU can modulate 1,2-dimethylhydrazine (DM H) induced histological and biochemical changes in the colon of Wistar rats. Methods: A Wistar rats CRC model was established and the animals were randomly d ivided into five groups. Rats in group A received a suspending vehicle . Group B rats received DMH t wice a week subcutaneously for 4 weeks. Animals in the other groups (C, D and E) received the same treatment of DMH, along with QU or 5 -FU (indiv idually) or combined QU+5-FU treat ment. Results: The DMH-treated rats developed adverse histological alterations (aberrant crypt foci, ACF) and biochemical changes (elevated serum CA19-9; reduced tissue levels of enzy mat ic antio xidants; elevated CDH12 p rotein expression and decreased SOX7 mRNA levels). Treat ment of DMH-treated animals with QU+5-FU (but not with QU or 5-FU, individually) significantly reversed these changes (i.e., suppressed the formation of ACF; decreased the CA19-9 levels; reduced CDH12 protein exp ression and increased SOX7 mRNA expression). Conclusions: Conclusively, to the best of our knowledge, our study was the first to evaluate the effects of QU+5-FU treat ment on the histological and molecu lar changes following DMH ad min istration in a rat colon model. Our data suggest that combination therapy with QU+5 -FU has therapeutic benefits in colon cancer induced by DMH, with potential for translation to spontaneous disease.
To date, and to the best of our knowledge, studies that evaluate the effects of combination treatment (DMH+QU+5-FU) versus individual therapy (DMH+5-FU or DMH+QU) on the histological and molecular changes in DMH-treated rat colon model are lacking. We carried out this work to test our hypothesis and to address these issues.
Materials and methods

Chemicals:
Dimethylhydrazine and QU were purchased from Sigma-Aldrich GmbH (Munich, Germany). (Selangor Darul Ehsan, Malaysia) to amplify the rat SOX7 and β-actin cDNA (Table 1) . All other chemicals, reagents, and solvents (of analytical grade) were obtained from standard suppliers and were used without further purification.
Animals and experimental design
The experiments were performed after approval of 
Biochemical estimations:
The analyses (biochemical estimations, Western was based on the Griess reaction, in which a chromophore with a strong absorbance at 545 nm is formed by reaction of NO2 with a mixture of naphthlethylenediamine and sulfanilamide [29] .
Results were expressed as µmol/g tissue.
Investigation of CDH12 expression by Western blot technique:
The colonic tissue homogenates were prepared in ice-cold Tris-HCl lysis buffer, pH 7.4 containing 1% protease inhibitor cocktail using Potter- 
Detection of SOX7 mRNA using reverse transcriptase PCR (RT-PCR):
In order to obtain a maximum intact RNA yield, a part of the colonic tissue was harvested in a specific lysis buffer supplied in total RNA purification kit using a Potter-Elvehjem rotor- 
Statistical analysis:
Statistical analyses of the data were carried out using Graphpad prism version 5.0 (Graphpad software San Diego, USA). Data comparisons were performed using analysis of variance Two deaths were recorded in the DMH group on days 50 and 73, i.e., the 36th and the 59th days after starting DMH injection. In (DMH+QU) group, only one animal died on day 65, i.e., the 51st day after starting DMH injection. In results is presented in Figure 3 and Table 2 .
Combination treatment with QU and 5-FU was associated with decreased serum levels of CA19-9
As compared to the healthy control group, serum levels of CA19-9 were significantly high in The intake of DMH was associated with the development of dysplastic ACF. The intake of a single agent (either 5-FU or QU) was associated with decreasing numbers of dysplastic ACF. The latter were completely absent following the combination treatment (DM H+QU+5-FU). DMH, 1,2-dimethylhydrazine; QU, Quercetin; 5-FU, 5-fluorouracil. decreased the serum of CA19-9 levels; reduced CDH12 protein expression and increased SOX7 mRNA expression). To the best of our knowledge, the current work was the first to address the molecular alterations of CDH12 and SOX7
(promising biomarkers in CRC) in DMH-treated rat colon.
Combination treatment with QU and 5-FU ameliorated weigh loss following DMH treatment
Weight loss is a common complication of the gastrointestinal neoplasms [37] . In agreement with other reports, we found that DMH-injected animals failed to gain weight whereas the healthy control group gained significant weights [38] . The DMHinduced failure to gain weight is reasoned to decreased food intake secondary to neoplastic transformation [39] , together with altered glucose metabolism with increased hepatic gluconeogenesis depleting the energy sources [22] . The weight loss observed in the 5-FU treated group (DMH+5-FU), is possibly due to 5-FU induced mucositis which occurs in ~60% of cancer patients receiving this drug [40] . In contrast, DMH-induced failure to gain weight was significantly ameliorated in animals receiving combination treatment (DMH+QU+5-FU). This is probably due to the ability QU to prevent 5-FU-induced mucositis through its antiinflammatory, antioxidant effects [41] and its potential to promote wound healing [42] .
Combination treatment with QU and 5-FU was associated with decreased serum levels of CA19-9
In agreement with other studies, we found a significantly increased serum levels of CA19-9
following DMH injection as compared to the healthy control group [14] . This is probably due to the inflammation associated colonic tissue damage secondary to the release of the reactive oxygen radicals [43] . Also, elevated preoperative serum CA 19-9 level may be useful in predicting peritoneal metastasis in colorectal cancer [44, 45] . 
Combination treatment with QU and 5-FU was associated with down-regulation of CDH2 protein
The upregulation of CDH12 protein following DMH administration with the development of ACF is consistent with the fact that CDH12 promotes proliferation and tumorigenesis [46, 47] . This In support, SOX7 over-expression suppressed cell proliferation and colony formation in prostate and CRC cell lines and induced apoptosis in CRC cells [49, 50] . Moreover, SOX7 upregulation inhibits proliferation, migration, and invasion of breast cancer cells in vitro and tumor growth in vivo [54] .
Taken together, SOX7 acts as a tumor suppressor and has a great potential to serve as a prognostic marker for cancer patients [54] . 
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